Research and Development

Kaiku Health is developed according to the principles of Evidence-Based Medicine.

Product Pipeline

We are continuously engaged in clinical research to further develop Kaiku Health.

In collaboration with cancer research institutes, clinics and life sciences partners, we strive for being the forerunner in digital management of the most novel cancer therapies.

Program
Therapeutic area
Initiated
Discovery stage
Poc stage
Pivotal stage
KH-ICI
Immune checkpoint inhibitor therapies
KH-CRC
Colorectal cancer
KH-MEDONC
Chemo- and targeted therapies
KH-PCA
Urological cancers
KH 26
Hematological cancers
KH 11
CAR-T Cell therapies

Publications

Concluded studies

Patient-reported outcome (PRO) follow-up has been shown to improve quality of life (QoL) and survival of cancer patients receiving chemotherapy. Kaiku Health application is a web-based electronic PRO (ePRO) tool which is designed for follow-up of cancer patients receiving immune checkpoint inhibitors (ICI). Purpose of the current study is to investigate whether symptoms collected by Kaiku Health ePRO tool on cancer patients receiving immune checkpoint inhibitors (ICI) follows to symptoms reported in clinical trials and whether coupling of specific symptoms does occur.

Iivanainen, S., Alanko, T., Peltola, K. et al.

Journal of Cancer Research and Clinical Oncology (2019) 145: 765.

Read publication

A Novel Digital Patient-Reported Outcome Platform for Head and Neck Oncology Patients

Clinical Medicine Insights: Ear, Nose and Throat 2016:9 1–6

Read publication

The patient’s role in toxicity reporting is increasingly acknowledged. There is also a need for developing modern communication methods between the patient and the medical personnel. Furthermore, the increasing number of head and neck cancer (HNC) patients is reflected in the volume of treatment follow-up visits, which remains a challenge for the health care. Electronic patient-reported outcome (ePRO) measures may provide a cost-efficient way to organize follow-up for cancer patients.

Maria K. Peltola, Joel S. Lehikoinen, Lauri T. Sippola, Kauko Saarilahti, Antti A. Mäkitie

Clinical Medicine Insights: Ear, Nose and Throat 2016:9 1–6

Read publication

A collaboration with HUCH Comprehensive Cancer Center and Aalto University: How to use visualizations to communicate the risk of GIST recurrence

The GIST Risk Calculator is accessible online for all cancer care and research professionals.

Online risk calculator

Online calculator visualizes the risk of gastrointestinal stromal tumor (GIST) recurrence and helps the doctors to evaluate the need for additional treatment after surgery. GIST Risk calculator is based on a research containing an international sample of 2000 diagnosed GIST-patients published in 2012 by HUCH Cancer Center and Aalto University.

The GIST Risk Calculator is accessible online for all cancer care and research professionals.

Online risk calculator

More Insight

Whitepapers

Read our whitepapers for more insights and discussion on the use of digital services in cancer care.

Contact

Get in touch with us

Interested in learning more about Kaiku Health? Send us a note
This form collects your name and email for communication purposes. Check out our privacy policy for further info on how we protect and manage your submitted data.